BG108261A - Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства - Google Patents

Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства Download PDF

Info

Publication number
BG108261A
BG108261A BG108261A BG10826103A BG108261A BG 108261 A BG108261 A BG 108261A BG 108261 A BG108261 A BG 108261A BG 10826103 A BG10826103 A BG 10826103A BG 108261 A BG108261 A BG 108261A
Authority
BG
Bulgaria
Prior art keywords
methyl
group
formula
hydrogen
atom
Prior art date
Application number
BG108261A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Original Assignee
Sanofi - Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Synthelabo filed Critical Sanofi - Synthelabo
Publication of BG108261A publication Critical patent/BG108261A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG108261A 2001-04-27 2003-10-13 Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства BG108261A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone

Publications (1)

Publication Number Publication Date
BG108261A true BG108261A (bg) 2004-12-30

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
BG108261A BG108261A (bg) 2001-04-27 2003-10-13 Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства
BG108260A BG108260A (bg) 2001-04-27 2003-10-13 Приложение на пиридоиндолонови производни за получаване на противоракови лекарства

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG108260A BG108260A (bg) 2001-04-27 2003-10-13 Приложение на пиридоиндолонови производни за получаване на противоракови лекарства

Country Status (33)

Country Link
US (3) US7524857B2 (https=)
EP (2) EP1385512B1 (https=)
JP (2) JP2004531538A (https=)
KR (1) KR100847413B1 (https=)
CN (2) CN1240382C (https=)
AR (1) AR034313A1 (https=)
AT (2) ATE314070T1 (https=)
BG (2) BG108261A (https=)
BR (1) BR0209138A (https=)
CA (2) CA2443012C (https=)
CY (1) CY1105813T1 (https=)
CZ (2) CZ299465B6 (https=)
DE (2) DE60208365T2 (https=)
DK (2) DK1385513T3 (https=)
EA (1) EA005930B1 (https=)
EE (2) EE200300465A (https=)
ES (2) ES2254683T3 (https=)
FR (1) FR2823975B1 (https=)
HU (2) HUP0400744A2 (https=)
IL (4) IL158266A0 (https=)
IS (1) IS2441B (https=)
MX (1) MXPA03009639A (https=)
NO (2) NO20034785L (https=)
NZ (1) NZ528671A (https=)
PL (2) PL366910A1 (https=)
PT (2) PT1385512E (https=)
RS (2) RS50791B (https=)
RU (1) RU2292888C9 (https=)
SK (2) SK13252003A3 (https=)
TW (1) TWI252104B (https=)
UA (1) UA74876C2 (https=)
WO (2) WO2002087575A1 (https=)
ZA (1) ZA200307785B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) * 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
JP2002510686A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CN1240382C (zh) 2006-02-08
CN1505511A (zh) 2004-06-16
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
ATE338548T1 (de) 2006-09-15
CZ20032909A3 (en) 2004-06-16
CA2444334A1 (fr) 2002-11-07
SK13242003A3 (sk) 2004-03-02
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
IL158312A (en) 2009-09-01
US20050272760A1 (en) 2005-12-08
IS2441B (is) 2008-11-15
US7160895B2 (en) 2007-01-09
BR0209138A (pt) 2004-06-08
CZ299465B6 (cs) 2008-08-06
KR100847413B1 (ko) 2008-07-18
SK13252003A3 (sk) 2004-03-02
EA200301062A1 (ru) 2004-04-29
US20040122027A1 (en) 2004-06-24
YU83403A (sh) 2006-08-17
US6967203B2 (en) 2005-11-22
PL366910A1 (en) 2005-02-07
BG108260A (bg) 2004-12-30
KR20040015138A (ko) 2004-02-18
IL158266A (en) 2009-09-01
DE60208365T2 (de) 2006-09-07
WO2002087575A1 (fr) 2002-11-07
ES2271264T3 (es) 2007-04-16
DE60214533T2 (de) 2007-06-21
DK1385513T3 (da) 2007-01-15
EP1385512B1 (fr) 2005-12-28
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
CZ295224B6 (cs) 2005-06-15
HK1060066A1 (en) 2004-07-30
RS50790B (sr) 2010-08-31
PT1385513E (pt) 2007-01-31
EE200300466A (et) 2003-12-15
EE200300465A (et) 2003-12-15
JP2004528343A (ja) 2004-09-16
ZA200307785B (en) 2004-10-06
WO2002087574A3 (fr) 2003-02-13
PL366916A1 (en) 2005-02-07
US20040122036A1 (en) 2004-06-24
DE60214533D1 (de) 2006-10-19
IL158312A0 (en) 2004-05-12
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
RS50791B (sr) 2010-08-31
PT1385512E (pt) 2006-05-31
JP2004531538A (ja) 2004-10-14
AR034313A1 (es) 2004-02-18
HK1059895A1 (en) 2004-07-23
CY1105813T1 (el) 2011-02-02
ES2254683T3 (es) 2006-06-16
ATE314070T1 (de) 2006-01-15
CN1505510A (zh) 2004-06-16
NO20034785D0 (no) 2003-10-24
RU2003130376A (ru) 2005-04-10
US7524857B2 (en) 2009-04-28
RU2292888C2 (ru) 2007-02-10
NO20034787D0 (no) 2003-10-24
HUP0400745A2 (hu) 2004-08-30
CA2443012A1 (en) 2002-11-07
IS6984A (is) 2003-10-09
CZ20032910A3 (en) 2004-07-14
FR2823975A1 (fr) 2002-10-31
CA2443012C (fr) 2009-07-28
NO20034787L (no) 2003-12-23
EP1385513B1 (fr) 2006-09-06
DK1385512T3 (da) 2006-05-22
YU83903A (sh) 2006-08-17
NZ528671A (en) 2004-06-25
EP1385513A1 (fr) 2004-02-04
MXPA03009639A (es) 2004-06-30
UA74876C2 (en) 2006-02-15
EA005930B1 (ru) 2005-08-25
HUP0400744A2 (hu) 2004-06-28

Similar Documents

Publication Publication Date Title
US9616081B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
US20090042924A1 (en) Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics
BG108261A (bg) Фармацевтични комбинации, основани на пиридоиндолонови производни и противоракови средства
RU2657604C2 (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
NZ740252A (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
HK1059895B (en) Use of pyridoindolone derivatives for preparing anticancer medicines